Point-of-care therapeutic drug monitoring

Point-of-care therapeutic drug monitoring (TDM) in cancer chemotherapy

Over the years, engineering of more sensitive and specific enzymes, have led to the development of small, portable instrumentations for rapid drug testing.

  • The problem: Chemotherapeutic drugs have very narrow therapeutic indices and highly variable pharmacokinetics, causing multiple side-effects and low efficacy.
  • The solution: A Point-of-care biosensor allows the direct monitoring of drug concentration in serum, affording real time adjustment of the dosage according to the characteristics of the individual being treated (personalized treatment).